Strontium ranelate - a promising therapeutic principle in osteoporosis

INSERM, UMR 1033, F-69372 Lyon, France.
Journal of Trace Elements in Medicine and Biology (Impact Factor: 2.49). 05/2012; 26(2-3):153-6. DOI: 10.1016/j.jtemb.2012.03.013
Source: PubMed

ABSTRACT Strontium ranelate (2g/day) appears to be a safe and efficient treatment of osteoporosis (OP), reducing the risks of both vertebral and non-vertebral fractures (including hip) in a wide variety of patients. Thus, the agent can now be considered as a first-line option to treat women at risk of OP fractures, whatever their age and the severity of the disease. A long-term treatment with strontium ranelate in OP women leads to a continued increase in bone mineral density at spine and hip levels, and a sustained antifracture efficacy. The mode of action of strontium ranelate involves a dissociation between bone resorption and formation, as the bone formation rate is increased and not influenced by the antiresorptive action of the agent. Strontium is heterogeneously distributed in bone tissue: it is absent from old bone tissue and is exclusively present in bone formed during the treatment. Total area containing strontium in bone tissue increases during treatment, although the focal bone strontium content is constant. Whatever the duration of treatment and the content of strontium in bone, the degree of mineralization is maintained in a normal range. Furthermore, no change at crystal level is detected up to 3 years of treatment.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with myeloma develop localized and generalized bone loss leading to hypercalcaemia, accelerated osteoporosis, vertebral wedge fractures, other pathological fractures, spinal cord compression and bone pain. Bone loss is mediated by a variety of biological modifiers including osteoclast-activating factors (OAF) and osteoblast (OB) inhibitory factors produced either directly by malignant plasma cells (MPCs) or as a consequence of their interaction with the bone marrow microenvironment (BMM). Raised levels of OAFs such as receptor activator of nuclear factor-kappa B ligand (RANKL), macrophage inflammatory protein 1 alpha, tumour necrosis factor-alpha and interleukin 6 stimulate bone resorption by recruiting additional osteoclasts. Via opposing mechanisms, increases in OB inhibitory factors, such as dickkopf-1 (Dkk-1), soluble frizzled-related protein-3 and hepatocyte growth factor (HGF), suppress bone formation by inhibiting the differentiation and recruitment of OBs. These changes result in an uncoupling of physiological bone remodelling, leading to myeloma bone disease (MBD). Moreover, the altered BMM provides a fertile ground for the growth and survival of MPCs. Current clinical management of MBD is both reactive (to pain and fractures) and preventive, with bisphosphonates (BPs) being the mainstay of pharmacological treatment. However, side effects and uncertainties associated with BPs warrant the search for more targeted treatments for MBD. This review will summarize recent developments in understanding the intimate relationship between MBD and the BMM and the novel ways in which they are being therapeutically targeted.
    British Medical Bulletin 09/2014; 111(1):117-38. DOI:10.1093/bmb/ldu016 · 3.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The present study investigated the effect of two single nucleotide polymorphisms (SNPs) of the vitamin D receptor (VDR) gene, rs1544410 A/G and rs2228570 C/T, in modulating bone mineral density (BMD) and the response to treatment with bisphosphonates or strontium ranelate in postmenopausal osteoporosis (PMO). Four hundred eighteen postmenopausal women from Southern Italy treated with bisphosphonates or strontium ranelate for three years were enrolled and stratified according to their genotype. Changes in BMD were expressed as the delta t-score (Δt-score). Allelic frequencies for rs1544410 A/GSNP were 11.2% AA, 50.0% GA and 38.8% GG; for rs2228570 C/TSNP were 54.8% CC, 39.5% TC and 5.7% TT. TT carriers showed a lower t-score than TC and CC (both p < 0.02) genotypes and were more responsive to the therapy when compared to both TC (p < 0.02) and CC (p < 0.05) carriers. Specifically, TT carriers receiving alendronate demonstrated a significant improvement of the Δt-score compared to TC and CC (both p < 0.0001) carriers. After adjustment for confounders, the Δt-score showed evidence of a statistically significant positive association with TT in all treatments considered. Therapy response was independent of rs1544410 A/G SNP; instead, rs2228570 C/TSNP was associated with a better response to antiresorptive treatment, thus suggesting that the therapy for PMO should be personalized.
    International Journal of Molecular Sciences 03/2015; 16(3):5452-5466. DOI:10.3390/ijms16035452 · 2.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Strontium ranelate (29 μg/ml) and ibandronic acid (50 μM) produced a cytotoxic effect on rat bone marrow myelokaryocytes in vitro. Strontium ranelate increased the number of myelokaryocytes with signs of necrosis, ibandronic acid increased the number of apoptotic and necrotic cells in the 9-day 2D culture of bone marrow cells on the plastic surface of the wells of culture plates. Co-culturing of the bone marrow with 3D matrices with microarc calcium phosphate coating that simulated bone mineral matrix increased intracellular ROS concentration, but abolished the cytotoxic effect of these drugs.
    Bulletin of Experimental Biology and Medicine 06/2014; 157(2). DOI:10.1007/s10517-014-2528-7 · 0.37 Impact Factor


Available from
Oct 6, 2014